Protein Summary
Acts as an adapter for the receptor ERBB2, in epithelia. By binding the unphosphorylated 'Tyr-1248' of receptor ERBB2, it may contribute to stabilize this unphosphorylated state (PubMed:16203728). Inhibits NOD2-dependent NF-kappa-B signaling and proinflammatory cytokine secretion (PubMed:16203728). This gene is a member of the leucine-rich repeat and PDZ domain (LAP) family. The encoded protein contains 17 leucine-rich repeats and one PDZ domain. It binds to the unphosphorylated form of the ERBB2 protein and regulates ERBB2 function and localization. It has also been shown to affect the Ras signaling pathway by disrupting Ras-Raf interaction. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Nov 2011]
- ENST00000284037
- ENSP00000284037
- ENSG00000112851
- ENST00000380935
- ENSP00000370322
- ENST00000380938
- ENSP00000370325
- ENST00000380943
- ENSP00000370330
- ENST00000506030
- ENSP00000426632
- ENST00000508515
- ENSP00000422015
- ENST00000511297
- ENSP00000422766
- ERBB2IP
- KIAA1225
- LAP2
- LAP2
- ERBB2IP
- HEL-S-78
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
biological process | 0 | ||
biological term | 0 | ||
cell line | 0 | ||
cell type or tissue | 0 | ||
cellular component | 0 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 96.91 (req: < 5)
Gene RIFs: 35 (req: <= 3)
Antibodies: 169 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 96.91 (req: >= 5)
Gene RIFs: 35 (req: > 3)
Antibodies: 169 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 19
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0